AbbVie teams with pharma firm to develop cancer drug
AbbVie Inc. could pay for a pharmaceutical firm in Massachusetts more than $800 million in a collaboration on a potential treatment for cancer. Cambridge,...
Knight Therapeutics acquires Orphan Canada
Knight Therapeutics, a leading Canadian specialty pharmaceutical company, has entered into an agreement of purchase of assets with Orphan Canada (orphan) related to the...
China’s pharmaceutical company launches operations in U.S.
Tasly Holding Group, a leading pharmaceutical company in China, officially launched its North American operations in the state of Maryland Wednesday as part of...
Antares Pharma to Participate at the Morgan Stanley Healthcare Conference
Antares Pharma, Inc. today announced that Eamonn P. Hobbs, President and Chief Executive Officer and Robert F. Apple, Chief Financial Officer and President of...
Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical
The board of directors of Luye Pharma Group Ltd., announced yesterday that the Company had entered into an agreement to purchase 57.98% stake of...
Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical
The board of directors of Luye Pharma Group Ltd., announced yesterday that the Company had entered into an agreement to purchase 57.98% stake of...
UCC RESEARCH TO HELP MALARIA VACCINE DEVELOPMENT
Researchers at UCC have developed a microneedle-based patch that results in increased vaccine-induced protection against malaria infection using lower doses of vaccine in...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...